MedPath
Found 21 clinical trials|View Analysis
Sort by:

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

Phase 1
Not yet recruiting
Conditions
Relapsed Adult AML
Interventions
Drug: CAR-T cell therapy
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
University Hospital, Lille
Target Recruit Count
5
Registration Number
NCT06649227

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Phase 1
Not yet recruiting
Conditions
Relapsed Adult AML
Interventions
Drug: zelenirstat
First Posted Date
2024-09-25
Last Posted Date
2024-12-13
Lead Sponsor
Pacylex Pharmaceuticals
Target Recruit Count
35
Registration Number
NCT06613217

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1
Withdrawn
Conditions
Refractory AML
Relapsed Adult AML
Interventions
First Posted Date
2024-09-06
Last Posted Date
2024-09-06
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registration Number
NCT06586099
Locations
🇨🇳

HBDH, Tianjin, Tianjin, China

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Phase 1
Recruiting
Conditions
Relapsed Adult AML
Refractory AML
Interventions
Drug: anti-CLL-1 CAR NK cells
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
24
Registration Number
NCT06307054
Locations
🇨🇳

Shanghai General Hospital, Shanghai, Shanghai, China

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Phase 2
Active, not recruiting
Conditions
Relapsed Adult ALL
Relapsed Adult AML
Interventions
First Posted Date
2023-11-21
Last Posted Date
2023-11-21
Lead Sponsor
The First Hospital of Jilin University
Target Recruit Count
28
Registration Number
NCT06141304
Locations
🇨🇳

First Hospital of Jilin University, Changchun, Jilin, China

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Phase 2
Recruiting
Conditions
AML, Adult
Refractory AML
Relapsed Adult AML
FLT3-TKD Mutation
FLT3-ITD
Interventions
First Posted Date
2023-09-01
Last Posted Date
2024-02-06
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
33
Registration Number
NCT06022003
Locations
🇫🇷

Paris Saint Louis, Paris, France

🇫🇷

Créteil CHU HENRI MONDOR, Créteil, France

🇫🇷

Angers CHU, Angers, France

and more 17 locations

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2023-08-23
Last Posted Date
2024-08-13
Lead Sponsor
Medical College of Wisconsin
Registration Number
NCT06007911
Locations
🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Phase 2
Recruiting
Conditions
Leukemia, Myeloid, Acute
Refractory Leukemia
Relapsed Adult AML
Interventions
First Posted Date
2022-03-31
Last Posted Date
2023-12-08
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Target Recruit Count
30
Registration Number
NCT05305859
Locations
🇨🇳

Bing Xu, Xiamen, Fujian, China

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Not Applicable
Recruiting
Conditions
Relapsed Adult AML
Primary Refractory Acute Myeloid Leukemia
High Risk Acute Myeloid Leukemia
Interventions
Behavioral: Primary Palliative Care
Behavioral: Specialty Palliative Care
First Posted Date
2022-02-14
Last Posted Date
2024-03-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
2300
Registration Number
NCT05237258
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

and more 17 locations

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Completed
Conditions
FLT3-TKD Mutation
FLT3-ITD
Refractory AML
Relapsed Adult AML
First Posted Date
2022-01-14
Last Posted Date
2023-05-24
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
177
Registration Number
NCT05193448
Locations
🇫🇷

Versailles CH, Versailles, France

🇫🇷

Villejuif IGR, Villejuif, France

🇫🇷

Bayonne CH, Bayonne, France

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath